Novo Nordisk's amycretin trial results highlight significant weight loss in adults with obesity, with further clinical ...

Novo Nordisk on Friday announced early-stage trial results for its amycretin obesity drug for subcutaneous injection, saying ...

The Danish pharma giant posted impressive data for amycretin one month after the disappointing readout of CagriSema.

Novo Nordisk's weight loss candidate in question is called amycretin. The company is developing an oral and a subcutaneous version of this medicine. Amycretin is a GLP-1 agonist, but it also ...

Novo Nordisk's experimental obesity drug amycretin demonstrated promising weight loss results in an early-stage trial, with participants losing 22% of their body weight in 36 weeks. This news boosted ...

Amycretin could give Novo a buzzy product in an newly competitive obesity market. It works similarly to existing GLP-1 ...

Novo Nordisk, a leading global healthcare company, announced topline results from a phase 1b/2a clinical trial with amycretin, a unimolecular GLP-1 and amylin receptor agonist intended for once weekly ...

On Friday, Novo Nordisk A/S (NYSE:NVO) released topline results from a phase 1b/2a trial with amycretin intended for once-weekly subcutaneous administration. The trial investigated the safety ...